Idarubicine
Advanced Malignancy
Junpeng WangPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Advanced Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Amg 232 Kartos Therapeutics, Inc. | Phase 1 | CCC |
Raltitrexed Junpeng Wang | Phase 2 | CCC |
Amg 337 Amgen | Phase 1 | CC |
Amg 820 AmMax Bio, Inc. | Phase 1 | CC |
POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X) SynDevRx, Inc. | Phase 1 | CC |
Amg 228 Amgen | Phase 1 | CC |
Adcx-020 Adcytherix SAS | Phase 1 | CC |
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →